ImaCor Inc., an innovative manufacturer of hemodynamic management devices, has developed the ImaCor ClariTEE, a miniaturized TEE probe. Through hTEE technology, the ClariTEE probe uniquely may remain indwelling for up to 72 hours providing direct visualization of the heart over time, thereby enabling gold standard hemodynamic management.

Hemodynamic management of critically ill patients is a constant challenge for the clinician and intensivist. Indirect measures such as cardiac filling pressures and flow data have known limitations in the ICU and the use of pulmonary artery catheters has declined due to ineffectiveness and increased risk.

The ClariTEE is effective not only in rapidly assessing the etiology of hemodynamic instability such as filling, function and the presence of effusion or tamponade, it is also effective in assessing changes as medical interventions such as administration of volume or inatropic agents are made.

The ClariTEE probe is designed for ease of use in the perioperative and ICU areas of the hospital by intensivists who care for these patients. While not designed to be a replacement for introperative TEE, it extends the hemodynamic assessment capabilities of TEE from the operating room to the ICU in post-cardiac surgery patients, and provides new hemodynamic management capabilities in non-cardiac surgical and patients.

hTEE means that hemodynamic management data is obtained easily, rapidly and accurately. For the first time, gold standard TEE driven management of a patient’s hemodynamic status is available over time. The opportunity for critical care units is that, using the ClariTEE, the right data is available at the right time. Wasteful utilization of resources due to management decisions based on incomplete information is replaced by cost optimization and an increase in ICU effectiveness.